Active, not recruitingInterventional · Phase 3NCT01901094 ↗A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Active, not recruitingInterventional · Phase 3NCT02193282 ↗Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)Ashish SaxenaPIInterventionOther: Clinical Observation · Drug: Erlotinib Hydrochloride · Other: Laboratory Biomarker Analysis · Other: Placebo AdministrationDatesFeb 2015 – Dec 2025SponsorAlliance for Clinical Trials in OncologyLung Non-Squamous Non-Small Cell CarcinomaStage IB Lung Non-Small Cell Carcinoma AJCC v7Stage II Lung Non-Small Cell Cancer AJCC v7+3 more
RecruitingInterventional · Phase 3NCT02582697 ↗Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell TumoursAlexander Ja-Ho ChouPIInterventionDrug: Bleomycin (active name: Bleomycin Sulfate) · Drug: Etoposide · Drug: Cisplatin · Drug: Pegylated G-CSF (Pegfilgrastim) · Drug: FilgrastimDatesFeb 2014 – Dec 2029 (est.)SponsorChildren's Oncology GroupGerm Cell Tumor
Active, not recruitingInterventional · Phase 3NCT02954874 ↗A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant ChemotherapyEleni AndreopoulouPIInterventionProcedure: Biospecimen Collection · Other: Laboratory Biomarker Analysis · Other: Patient Observation · Biological: Pembrolizumab · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation TherapyDatesJan 2017 – Aug 2026SponsorSouthwest Oncology GroupBreast Carcinoma In SituInvasive Breast CarcinomaStage I Breast Cancer AJCC v7+3 more
Active, not recruitingInterventional · Phase 3NCT03105102 ↗A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's DiseaseAliza B SolomonPIInterventionDrug: Placebo for Risankizumab SC · Drug: Risankizumab IV · Drug: Placebo for Risankizumab IV · Drug: Risankizumab SC · Drug: Risankizumab On-Body Injector (OBI)DatesApr 2018 – Feb 2029 (est.)SponsorAbbVie Inc.Crohn's Disease
Active, not recruitingInterventional · Phase 3NCT03301506 ↗ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)Sonal KumarPIInterventionDrug: Seladelpar 5 mg Capsule · Drug: Seladelpar 10 mg CapsuleDatesDec 2017 – Nov 2028 (est.)SponsorGilead Sciences, Inc.Primary Biliary Cirrhosis
Active, not recruitingInterventional · Phase 3NCT03488693 ↗TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerHani Lamie AshamallaPIInterventionRadiation: Radiation · Other: No RadiationDatesOct 2018 – Sep 2027 (est.)SponsorCanadian Cancer Trials GroupBreast Cancer
Active, not recruitingInterventional · Phase 3NCT03533582 ↗Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)Alexander Ja-Ho ChouPIInterventionProcedure: Biospecimen Collection · Drug: Carboplatin · Drug: Cisplatin · Drug: Doxorubicin · Drug: Etoposide · Drug: Fluorouracil · Drug: Gemcitabine · Drug: Irinotecan · Drug: Oxaliplatin · Other: Patient Observation · Procedure: Resection · Drug: Sorafenib · Drug: Vincristine SulfateDatesMay 2018 – Mar 2027 (est.)SponsorChildren's Oncology GroupChildhood Hepatocellular CarcinomaChildhood Malignant Liver NeoplasmFibrolamellar Carcinoma+2 more
Active, not recruitingInterventional · Phase 3NCT03568383 ↗Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)Jean W. PapePIInterventionDrug: Delamanid (DLM) · Drug: Isoniazid (INH) · Dietary supplement: Pyridoxine (vitamin B6)DatesJun 2019 – Nov 2026 (est.)SponsorNational Institute of Allergy & Infectious DiseasesTuberculosis, MDR
Active, not recruitingInterventional · Phase 3NCT03602859 ↗A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerEloise ChapmanPIInterventionDrug: Niraparib · Drug: Dostarlimab (TSR-042) · Drug: Standard of care · Drug: Dostarlimab-Placebo · Drug: Niraparib-PlaceboDatesOct 2018 – Oct 2024· Results postedSponsorTesaro, Inc.Ovarian NeoplasmsOvarian, Fallopian Tube and Primary Peritoneal Carcinoma
Active, not recruitingInterventional · Phase 3NCT03653507 ↗A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaManish A ShahPIInterventionDrug: zolbetuximab · Drug: oxaliplatin · Drug: capecitabine · Drug: placeboDatesNov 2018 – Oct 2022· Results postedSponsorAstellas Pharma Global Development, Inc.Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
RecruitingInterventional · Phase 3NCT03678025 ↗Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate CancerDouglas S ScherrPIInterventionDrug: Abiraterone · Drug: Bicalutamide · Drug: Degarelix · Drug: Docetaxel · Drug: Flutamide · Drug: Goserelin Acetate · Drug: Histrelin Acetate · Drug: Leuprolide Acetate · Drug: Nilutamide · Procedure: Orchiectomy · Drug: Prednisone · Other: Quality-of-Life Assessment · Radiation: Radiation Therapy · Procedure: Radical Prostatectomy · Drug: TriptorelinDatesSep 2018 – Apr 2033 (est.)SponsorSouthwest Oncology GroupCastration Levels of TestosteroneMetastatic Prostatic AdenocarcinomaStage IV Prostate Cancer AJCC v8+2 more
Active, not recruitingInterventional · Phase 3NCT03682068 ↗A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.Scott T. TagawaPIInterventionDrug: Durvalumab · Drug: Tremelimumab · Drug: Cisplatin + Gemcitabine · Drug: Carboplatin + GemcitabineDatesSep 2018 – Jun 2026SponsorAstraZeneca Pharmaceuticals LPUnresectable Locally Advanced Urothelial CancerMetastatic Urothelial Cancer
Enrolling by invitationInterventional · Phase 3NCT03683186 ↗A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepag in Subjects With World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH)Evelyn M. HornPIInterventionDrug: RalinepagDatesSep 2019 – Dec 2026 (est.)SponsorUnited TherapeuticsPAHPulmonary HypertensionPulmonary Arterial Hypertension+8 more
Active, not recruitingInterventional · Phase 3NCT03725059 ↗A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)Eleni AndreopoulouPIInterventionBiological: Pembrolizumab (K) · Drug: Placebo (P) · Drug: Paclitaxel (X) · Drug: Doxorubicin (A) · Drug: Epirubicin (E) · Drug: Cyclophosphamide (C) · Drug: Endocrine therapy · Radiation: Radiation therapy · Procedure: SurgeryDatesDec 2018 – Jan 2031 (est.)SponsorMerck & Co., Inc.Breast Cancer
Active, not recruitingInterventional · Phase 3NCT03737981 ↗A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)John AllanPIInterventionDrug: Ibrutinib · Biological: Obinutuzumab · Other: Observation Activity · Drug: VenetoclaxDatesJan 2019 – Jan 2025· Results postedSponsorAlliance for Clinical Trials in OncologyChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Active, not recruitingInterventional · Phase 3NCT03765918 ↗A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)Doru PaulPIInterventionBiological: Pembrolizumab 200 mg · Radiation: Radiotherapy 60 Gray · Radiation: Radiotherapy 66 Gray · Radiation: Radiotherapy 70 Gray · Drug: Cisplatin 100 mg/m^2DatesDec 2018 – Jul 2024· Results postedSponsorMerck Sharp & Dohme CorpHead and Neck Neoplasms
Active, not recruitingInterventional · Phase 3NCT03767244 ↗A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyJim C. HuPIInterventionDrug: Apalutamide · Drug: Androgen Deprivation Therapy (ADT) · Drug: PlaceboDatesJun 2019 – Dec 2026 (est.)SponsorJanssen Research & Development, LLCProstatic Neoplasms
Active, not recruitingInterventional · Phase 3NCT03793166 ↗PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]Ana M. MolinaPIInterventionProcedure: Biospecimen Collection · Procedure: Bone Scan · Drug: Cabozantinib · Procedure: Computed Tomography · Biological: Ipilimumab · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Other: Quality-of-Life Assessment · Other: Questionnaire AdministrationDatesJun 2019 – Mar 2028 (est.)SponsorAlliance for Clinical Trials in OncologyClear Cell Renal Cell CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Lymph Nodes+6 more
Active, not recruitingInterventional · Phase 3NCT03803553 ↗Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon CancerManish A ShahPIInterventionDrug: FOLFIRI Protocol · Other: ACTIVE SURVEILLANCE · Drug: Nivolumab Protocol · Drug: Encorafenib/Binimetinib/Cetuximab Protocol · Drug: Trastuzumab + PertuzumabDatesApr 2020 – Dec 2026 (est.)SponsorThe General Hospital Corporation (dba Massachusetts General Hospital)Metastatic Colon CancerStage III Colon Cancer